Analysts expect Thermo Fisher Scientific Inc (NYSE:TMO) to post earnings per share (EPS) of $2.26 for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Thermo Fisher Scientific’s earnings. The lowest EPS estimate is $2.22 and the highest is $2.28. Thermo Fisher Scientific posted earnings of $2.03 per share during the same quarter last year, which suggests a positive year over year growth rate of 11.3%. The business is expected to issue its next earnings report on Thursday, July 27th.

On average, analysts expect that Thermo Fisher Scientific will report full year earnings of $9.22 per share for the current financial year, with EPS estimates ranging from $9.20 to $9.25. For the next fiscal year, analysts forecast that the firm will post earnings of $10.22 per share, with EPS estimates ranging from $10.03 to $10.81. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Thermo Fisher Scientific.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, April 26th. The medical research company reported $2.08 EPS for the quarter, topping the consensus estimate of $2.02 by $0.06. Thermo Fisher Scientific had a return on equity of 15.73% and a net margin of 11.58%. The business had revenue of $4.77 billion during the quarter, compared to analyst estimates of $4.68 billion. During the same period last year, the business posted $1.80 earnings per share. The company’s quarterly revenue was up 10.9% on a year-over-year basis.

A number of research firms have recently commented on TMO. Deutsche Bank AG set a $200.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Saturday, June 10th. Cantor Fitzgerald began coverage on Thermo Fisher Scientific in a report on Thursday, May 18th. They set an “overweight” rating and a $194.00 price objective for the company. Jefferies Group LLC restated a “hold” rating and set a $175.00 price objective on shares of Thermo Fisher Scientific in a report on Wednesday, May 17th. Barclays PLC restated an “overweight” rating and set a $190.00 price objective (up from $175.00) on shares of Thermo Fisher Scientific in a report on Tuesday, May 9th. Finally, Bank of America Corporation upped their price objective on Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, May 9th. Three investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $183.47.

In other Thermo Fisher Scientific news, insider Thomas W. Loewald sold 1,532 shares of the company’s stock in a transaction dated Thursday, April 27th. The shares were sold at an average price of $168.76, for a total value of $258,540.32. Following the completion of the transaction, the insider now directly owns 41,277 shares of the company’s stock, valued at approximately $6,965,906.52. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Daniel P. Shine sold 4,688 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $171.88, for a total transaction of $805,773.44. Following the completion of the transaction, the insider now directly owns 29,200 shares of the company’s stock, valued at $5,018,896. The disclosure for this sale can be found here. Over the last three months, insiders sold 28,720 shares of company stock valued at $4,960,764. 0.49% of the stock is currently owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. Clearbridge Investments LLC boosted its position in shares of Thermo Fisher Scientific by 16.6% in the first quarter. Clearbridge Investments LLC now owns 2,571,783 shares of the medical research company’s stock valued at $395,026,000 after buying an additional 365,409 shares during the last quarter. Perigon Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 2.1% in the first quarter. Perigon Wealth Management LLC now owns 30,854 shares of the medical research company’s stock valued at $4,744,000 after buying an additional 624 shares during the last quarter. Piedmont Investment Advisors LLC boosted its position in shares of Thermo Fisher Scientific by 0.9% in the first quarter. Piedmont Investment Advisors LLC now owns 83,285 shares of the medical research company’s stock valued at $12,793,000 after buying an additional 707 shares during the last quarter. Skandinaviska Enskilda Banken AB publ boosted its position in shares of Thermo Fisher Scientific by 1.5% in the first quarter. Skandinaviska Enskilda Banken AB publ now owns 63,315 shares of the medical research company’s stock valued at $9,725,000 after buying an additional 930 shares during the last quarter. Finally, HM Payson & Co. boosted its position in shares of Thermo Fisher Scientific by 55.4% in the first quarter. HM Payson & Co. now owns 10,665 shares of the medical research company’s stock valued at $1,638,000 after buying an additional 3,800 shares during the last quarter. 86.94% of the stock is owned by institutional investors.

Thermo Fisher Scientific (NYSE:TMO) traded up 0.82% on Monday, hitting $176.29. The stock had a trading volume of 116,491 shares. The company’s 50-day moving average price is $172.39 and its 200 day moving average price is $156.39. The firm has a market cap of $68.97 billion, a price-to-earnings ratio of 32.16 and a beta of 1.05. Thermo Fisher Scientific has a one year low of $139.07 and a one year high of $176.85.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 17th. Shareholders of record on Thursday, June 15th will be given a $0.15 dividend. The ex-dividend date of this dividend is Tuesday, June 13th. This represents a $0.60 dividend on an annualized basis and a yield of 0.34%. Thermo Fisher Scientific’s payout ratio is currently 10.95%.

TRADEMARK VIOLATION WARNING: This report was originally published by American Banking News and is owned by of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States and international copyright laws. The original version of this report can be read at https://www.americanbankingnews.com/2017/06/19/thermo-fisher-scientific-inc-tmo-expected-to-post-earnings-of-2-26-per-share.html.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Get a free copy of the Zacks research report on Thermo Fisher Scientific (TMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.